Timely scan could save lives of A&E patients with blood in urine
One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found. The WASHOUT study, presented today… read more.
One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found. The WASHOUT study, presented today… read more.
Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are presented today… read more.
Shionogi & Co. Ltd. announced that its group company, Shionogi China Co., Ltd, has received approval from the National Medical Products Administration (NMPA) of China for cefiderocol for… read more.
Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed alternative… read more.
NICE (UK): Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if: i) docetaxel is not… read more.
UCLA research finds that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the United States Preventive Services Task Force (USPSTF) lowered the recommended… read more.
Patients with colon cancer who are using glucagon-like peptide-1 (GLP-1) receptor agonists for blood sugar regulation and/or weight control appear to have achieved a significantly lower risk of… read more.
Guardant Health Inc announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening… read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
Novartis presented new Pluvicto(lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025…. read more.
Researchers report that overall survival is significantly longer among prostate cancer patients at high-risk of biochemical recurrence who are treated with combination enzalutamide and leuprolide rather than with… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that a presentation related to Peyronie’s disease, or PD, and Xiaflex (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.